Plasma of CLL patients also contains higher levels, compared with healthy donors, of other factors known to compromise NK cell function, such as macrophage migration inhibitory factor [192] and the soluble NKG2D ligands MIC-B and ULBP2 [148]. Here, MICB is linked to B-cell chronic lymphocytic leukemia.